[go: up one dir, main page]

TN2013000440A1 - Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids - Google Patents

Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids

Info

Publication number
TN2013000440A1
TN2013000440A1 TNP2013000440A TN2013000440A TN2013000440A1 TN 2013000440 A1 TN2013000440 A1 TN 2013000440A1 TN P2013000440 A TNP2013000440 A TN P2013000440A TN 2013000440 A TN2013000440 A TN 2013000440A TN 2013000440 A1 TN2013000440 A1 TN 2013000440A1
Authority
TN
Tunisia
Prior art keywords
methyl
organic acids
imidazol
pyridinyl
pyrimidinyl
Prior art date
Application number
TNP2013000440A
Other languages
French (fr)
Inventor
Shoufeng Li
Saran Kumar
Nikhil Javant Kavimandan
Enxian Lu
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2012/042205 external-priority patent/WO2012174082A1/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TN2013000440A1 publication Critical patent/TN2013000440A1/en

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Soluble pharmaceutical compositions of amorphous nilotinib or a pharmaceutically acceptable salt thereof were invented using one or more organic acids that function as a solubilizing agent, increasing the bioavailability of nilotinib and supressing the food effect associated with certain compositions of nilotinib. The pharmaceutical compositions are in th form of solid oral dosage forms, including capsules and tablets.
TNP2013000440A 2011-09-30 2013-10-29 Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids TN2013000440A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161541306P 2011-09-30 2011-09-30
PCT/US2012/042205 WO2012174082A1 (en) 2011-06-14 2012-06-13 Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids

Publications (1)

Publication Number Publication Date
TN2013000440A1 true TN2013000440A1 (en) 2015-03-30

Family

ID=52394773

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2013000440A TN2013000440A1 (en) 2011-09-30 2013-10-29 Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids

Country Status (2)

Country Link
CU (1) CU20130165A7 (en)
TN (1) TN2013000440A1 (en)

Also Published As

Publication number Publication date
CU20130165A7 (en) 2014-04-24

Similar Documents

Publication Publication Date Title
SG194756A1 (en) Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids
PH12016501310B1 (en) Pharmaceutical compositions comprising azd9291
EA201291421A1 (en) ORAL PHARMACEUTICAL MEDICINE FORMS CONTAINING ETEXILATE DAGIGATRAN AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS
SG10201810985XA (en) Tofacitinib oral sustained release dosage forms
EA201491285A1 (en) IMPROVED COMPOSITIONS AND METHODS OF DELIVERY OF OMEPRAZOL AND ACETYLSALICYLIC ACID
IL233282A (en) Crystalline forms of 5-(2,6-di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine monohydrochloride, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments
EA201201263A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING DAGIGATRAN ETEXYLATE
TN2012000371A1 (en) Pyrazole compounds as crth2 antagonists
EA201201202A1 (en) ORAL PHARMACEUTICAL COMPOSITION CONTAINING DABIGATRANE EXTILE
PH12015500823A1 (en) Modified release formulations for oprozomib
IL230487B (en) 6-(n-(7-chloro-1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-5- yl)methylsulfonamido)-5-cyclopropyl-2-(4-fluorophenyl)-n-methylbenzofuran-3-carboxamide compounds, pharmaceutically acceptable salts thereof and pharmaceutical composition comprising them
JO3587B1 (en) Oral dosage forms of bendamustine
TN2014000177A1 (en) Immediate release 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-methyl- 1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide formulation
IN2014CN02343A (en) Oral formulations containing hyaluronic acid for sustained drug release
TR201803451T4 (en) OLMESARTAN FORMULATIONS.
TN2013000440A1 (en) Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids
IN2012CH05549A (en)
WO2011161223A3 (en) Pharmaceutical oral dosage forms comprising lercanidipine and enalapril and their pharmaceutically acceptable salts
TH148311A (en) Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazole-1-yl)-3-(trifluoromethyl)phenyl] benzamide that can be dissolved using organic acids.
MA35169B1 (en) Modified release of 4-methyl-3- [[4- (3-pyridinyl) -2-pyrimidinyl] amino] -n-5- (4-methyl-1H-imidazol-1-yl) -3- (trifluoromethyl) phenyl] ] benzamide solubilized with organic acids
TH148311B (en) Modified release of 4- methyl-3 - [[4- (3-pyridinil) -2-pyrimidinyl] amino] -N- [5- (4-methyl-1H-imi Dasol-1-il) -3- (trifulformethyl) phenyl] soluble benzamides using organic acids
MY183976A (en) Pharmaceutical composition for oral administration with improved dissolution and/or absorption
TR201005911A2 (en) A drug formulation with improved dissolution profile.
UA110792C2 (en) Pharmaceutical form bendamustine for oral use
ES2422657A1 (en) Solid cilostazol pharmaceutical composition